Barely Significant
← all excerpts

Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.

Drug Des Devel Ther · 2018 · PMC5958944 · PMID 29795977

Europe PMCDOI
1
hedged sentence
0.0880
closest p · 1.8× alpha
0.0880
boldest claim

The sentences

a trend toward significancep =0.088so close (0.05 < p ≤ 0.1)
Similar results were found for VMAT-2 inhibitors as a class pertaining to response defined according to CGI criteria (k=9; RR =1.50; 95% CI =1.14, 1.97; p =0.003; I 2 =44.32%; NNT =6, 95% CI =3, 18, p =0.004), with consistent results for valbenazine (k=5; RR =2.06, 95% CI =1.24, 3.41; p =0.005; I 2 =59.96%; NNT =5, 95% CI =3, 62, p =0.034), while deutetrabenazine showed only a trend toward significance (k=4; RR =1.32; 95% CI =0.96,1.82; p =0.088; I 2 =0%; NNT =9, 95% CI =4, 200, p =0.041).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.